Dear Editor,

Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) were recently approved for the treatment of complicated intra-abdominal infections and complicated urinary tract infections (<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427534.htm>, <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm>, both accessed February 24, 2016). To date, only one study has simultaneously evaluated the activities of C/T and CZA *in vitro* against *Pseudomonas aeruginosa*, and few studies have evaluated the effects of these antibiotics on multi-drug resistant (MDR) gram-negative bacteria \[[@B1][@B2][@B3]\]. This study aimed to examine the activities of C/T and CZA against β-lactam-resistant *Enterobacteriaceae* and *P. aeruginosa* clinical isolates.

The isolates were recovered from clinical specimens at Barnes-Jewish Hospital (St. Louis, MO, USA) from September to December 2014. Specimen sources included respiratory, blood, urine, and wound samples. Isolates of *Enterobacteriaceae* were included if they tested non-susceptible to cefepime and/or had an extended-spectrum β-lactamase (ESBL)-producing phenotype. *P. aeruginosa* isolates were included if they tested non-susceptible to meropenem. We included carbapenem-resistant *Enterobacteriaceae* isolates recovered from August 2012 to December 2014; these strains were tested for the *bla*~KPC~ and *bla*~NDM~ genes by real-time PCR \[[@B4][@B5]\]. All isolates were negative for the *bla*~NDM~ gene.

Frozen stocks of all isolates were subcultured twice consecutively on 5% sheep\'s blood agar (Hardy Diagnostics, Santa Maria, CA, USA) prior to antimicrobial susceptibility testing (AST). Species-level identification was confirmed by using the VITEK MS system (IVD v2.3.3, bioMérieux, Durham, NC, USA) \[[@B6][@B7]\]. AST was performed by using gradient diffusion (Etest, bioMérieux). In brief, a 0.5 McFarland standard suspension of each isolate was inoculated onto Mueller-Hinton agar (Hardy Diagnostics), and Etest strips were applied. Plates were incubated overnight at 35℃ in ambient air. Each day, QC strains (*Escherichia coli* ATCC 25922 and ATCC 35218, and *P. aeruginosa* ATCC 27853) were tested. C/T and CZA results and QC were interpreted by using Food and Drug Administration breakpoints. The categorical interpretation and QC ranges for all other antibiotics (BD BBL and Co., Sparks, MD, USA) were based on standardized disk diffusion criteria \[[@B8]\].

We evaluated 120 clinical isolates comprising 45 *P. aeruginosa* strains and 75 *Enterobacteriaceae* strains. [Table 1](#T1){ref-type="table"} shows the overall β-lactam susceptibility profile. A subset of *P. aeruginosa* isolates (n=10, 22%), termed "β-lactam-resistant (BLR)", were resistant to piperacillin/tazobactam, cefepime, meropenem, and imipenem.

The 50% minimum inhibitory concentration (MIC~50~, 1 µg/mL) and 90% minimum inhibitory concentration (MIC~90~, 8 µg/mL) of C/T were lower for the *P. aeruginosa* isolates than for the *Enterobacteriaceae* isolates (2 µg/mL and 32 µg/mL, respectively; [Table 2](#T2){ref-type="table"}). Furthermore, 87% (n=39) of all *P. aeruginosa* isolates and 60% (n=6) of the BLR *P. aeruginosa* isolates were C/T-susceptible ([Table 2](#T2){ref-type="table"}).

Within the *Enterobacteriaceae*, the C/T data showed group-dependent differences. For example, the *E. coli* isolates had a low MIC~90~ (0.5 µg/mL), whereas the *Enterobacter* spp. had a higher MIC~90~ (64 µg/mL). Overall, 56% (n=42) of all *Enterobacteriaceae* isolates were C/T-susceptible ([Table 2](#T2){ref-type="table"}).

In contrast to the C/T results, the *Enterobacteriaceae* had lower MIC~50~ (0.5 µg/mL) and MIC~90~ (2 µg/mL) values for CZA compared to the *P. aeruginosa* isolates (2 µg/mL and 16 µg/mL, respectively; [Table 2](#T2){ref-type="table"}). Notably, 82% (n=37) of all *P. aeruginosa* isolates were CZA-susceptible ([Table 2](#T2){ref-type="table"}), whereas 99% (n=74) of *Enterobacteriaceae* isolates were CZA-susceptible. An *Enterobacter* spp. isolate was CZA-resistant (MIC of 32 µg/mL), but was found to be negative for the *bla*~KPC~ and *bla*~NDM~ genes by real-time PCR.

Comparison of the *P. aeruginosa* C/T and CZA results showed 87% (n=39) concordance with 35 isolates testing susceptible and four isolates testing non-susceptible to both antibiotics. For the *Enterobacteriaceae*, there was only a 57% concordance between the C/T and CZA results; 42 isolates tested susceptible and one isolate tested non-susceptible to both antibiotics. All remaining isolates were only CZA-susceptible.

The availability of new agents with anti-gram-negative activity holds promise for treating MDR organisms. CZA provides an alternative treatment for *bla*~KPC~-positive organisms, which are otherwise treated by agents with less desirable safety or efficacy profiles. Ceftolozane is a new cephalosporin with activity against *P. aeruginosa*, and in combination with tazobactam shows activity against ESBL-producing *Enterobacteriaceae* \[[@B9]\]. Notably, although two of the *bla*~KPC~-positive isolates were C/T-susceptible, we would not expect C/T to be clinically effective.

In summary, we report the activities of C/T and CZA against a collection of BLR *Enterobacteriaceae* and *P. aeruginosa* isolates. Our results suggest that C/T and CZA are active against and represent possible therapeutic options for infections with BLR gram-negative bacteria.
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###### β-Lactam susceptibility profiles of the study isolates (N=120)

![](alm-37-174-i001)

  Bacterial group (N)                       \% Susceptible^\*^                         
  ----------------------------------------- -------------------- ---- ---- ----- ----- -----
  *Pseudomonas aeruginosa* (45)             73                   67   71   13    NA    22
   BLR *P. aeruginosa*^†^ (10)              10                   0    0    0     NA    0
  *Enterobacteriaceae* (75)                 27                   40   21   64    57    73
   *Enterobacter* spp. (17)                 6                    6    12   35    12    47
   *Escherichia coli* (29)                  59                   86   28   100   100   100
   *Klebsiella pneumoniae* (24)             8                    17   8    42    42    63
    ESBL *K. pneumoniae* (8)                13                   50   25   100   100   100
    CRE *K. pneumoniae*^‡^ (16)             6                    0    0    13    13    44
  Remaining isolates^§^ (5)                 0                    0    80   60    40    60
  Enterobacteriaceae *bla*~KPC~ status^∥^                                              
   *bla*~KPC~ positive^¶^ (10)              0                    0    10   0     10    0
   *bla*~KPC~ negative^\*\*^ (65)           31                   46   23   74    65    85

^\*^Based on CLSI M100-S25 antibiotic disk diffusion criteria; ^†^BLR *P. aeruginosa* isolates were not susceptible to piperacillin-tazobactam, cefepime, meropenem, and imipenem; ^‡^CRE *K. pneumoniae*, carbapenem-resistant *K. pneumoniae* isolates that either tested positive for *bla*~KPC~ (n=8) or were negative for *bla*~KPC~ and *bla*~NDM~ (n=8) by real-time PCR; ^§^Remaining isolates, including *Citrobacter freundii* complex (n=3), *Klebsiella oxytoca* (n=1), and *Morganella morganii* (n=1); ^∥^*Enterobacteriaceae* *bla*~KPC~ status, all of the above *Enterobacteriaceae* isolates identified only by *bla*~KPC~ status; ^¶^*bla*~KPC~-positive, isolates that tested positive for *bla*~KPC~ by real-time PCR; ^\*\*^*bla*~KPC~-negative, isolates that either tested negative for *bla*~KPC~ and *bla*~NDM~ by real-time PCR (n=20) or lacked a phenotype (n=45) that is consistent with a *bla*~KPC~-positive organism (i.e., lack of resistance to meropenem).

Abbreviations: C/T, ceftolozane-tazobactam; CZA, ceftazidime-avibactam; MIC, minimum inhibitory concentration; NA, not applicable; ESBL, extended spectrum β-lactamase; CRE, carbapenem-resistant *Enterobacteriaceae*.

###### Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) activity against BLR gram-negative bacteria
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  Bacterial group (N)                       C/T MIC Range µg/mL   C/T MIC~50~   C/T MIC~90~   C/T % Sus^\*^   CZA MIC Range µg/mL   CZA MIC~50~   CZA MIC~90~   CZA % Sus^\*^
  ----------------------------------------- --------------------- ------------- ------------- --------------- --------------------- ------------- ------------- ---------------
  *Pseudomonas aeruginosa* (45)             0.25--16              1             8             87              0.5--64               2             16            82
   BLR *P. aeruginosa*^†^ (10)              2--16                 4             8             60              2--64                 8             64            50
  *Enterobacteriaceae* (75)                 0.125-- ≥ 256         2             32            56              0.032--32             0.5           2             99
   *Enterobacter* spp. (17)                 0.5--64               4             64            18              0.125--32             1             4             94
   *Escherichia coli* (29)                  0.125--4              0.25          0.5           97              0.032--2              0.125         0.5           100
   *Klebsiella pneumoniae* (24)             0.25-- ≥ 256          4             128           42              0.125--8              1             2             100
    ESBL *K. pneumoniae* (8)                0.25--4               0.25          4             88              0.125--1              0.25          1             100
    CRE *K. pneumoniae*^‡^ (16)             1-- ≥ 256             8             ≥ 256         19              1--8                  2             4             100
  Remaining isolates^§^ (5)                 2--16                 16            16            20              0.5--2                1             2             100
  *Enterobacteriaceae bla*~KPC~ status^∥^                                                                                                                       
   *bla*~KPC~ positive^¶^ (10)              2--128                8             128           20              0.5--4                1             2             100
   *bla*~KPC~ negative^\*\*^ (65)           0.125-- ≥ 256         0.5           16            62              0.032--32             0.25          2             99

^\*^% Sus, % Susceptible based on Food and Drug Administration interpretative criteria for ceftolozane-tazobactam and ceftazidime-avibactam; ^†^BLR *P. aeruginosa* isolates that were not susceptible to piperacillin-tazobactam, cefepime, meropenem, and imipenem; ^‡^CRE *K. pneumoniae*, carbapenem-resistant *K. pneumoniae* isolates that either tested positive for *bla*~KPC~ (n=8) or were negative for *bla*~KPC~ and *bla*~NDM~ (n=8) by real-time PCR; ^§^Remaining isolates, including *Citrobacter freundii* complex (n=3), *Klebsiella oxytoca* (n=1), and *Morganella morganii* (n=1); ^∥^*Enterobacteriaceae* *bla*~KPC~ status, all of the above *Enterobacteriaceae* isolates identified only by *bla*~KPC~ status; ^¶^*bla*~KPC~-positive, isolates that tested positive for *bla*~KPC~ by real-time PCR; ^\*\*^*bla*~KPC~-negative, isolates that either tested negative for *bla*~KPC~ and *bla*~NDM~ by real-time PCR (n=20) or lacked a phenotype (n=45) that is consistent with a *bla*~KPC~-positive organism (i.e., lack of resistance to meropenem).

Abbreviations: C/T, ceftolozane-tazobactam; CZA, ceftazidime-avibactam; MIC, minimum inhibitory concentration; ESBL, extended spectrum β-lactamase; CRE, carbapenem-resistant *Enterobacteriaceae*.
